Aquestive Therapeutics, Inc. AQST Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s other commercial liabilities?
- Aquestive Therapeutics, Inc. (AQST) reported other commercial liabilities of $3.45M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s other commercial liabilities changed year-over-year?
- Aquestive Therapeutics, Inc.'s other commercial liabilities increased by 4.1% year-over-year, from $3.31M to $3.45M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s other commercial liabilities has grown at a -10.1% compound annual growth rate (CAGR), from $8.57M to $5.03M.